Navigation Links
Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
Date:5/15/2008

/20 mg), 6.2% (5/40 mg), 13.3% (10/20 mg), and 11.2% (10/40 mg). The edema incidence for placebo was 12.3%.

Adverse reactions seen at lower rates but at about the same or greater incidence as in patients receiving placebo included hypotension, orthostatic hypotension, rash, pruritus, palpitation, urinary frequency, and nocturia.

In individual clinical trials of amlodipine and olmesartan medoxomil, other commonly reported adverse reactions included headache, dizziness, and flushing.

For more information on AZOR, call 877-4-DSPROD (877-437-7763) or go to the web site http://www.azor.com.

About Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan's second largest pharmaceutical company and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders.

For more information, please visit http://www.dsus.com.

* SeDBP = Seated Diastolic Blood Pressure. According to the JNC 7, a

SeDBP between 90 and 99 is considered stage 1 hypertension and 100

and above is considered stage 2 hypertension.

(1) Ong KL, et al. Prevalence, awareness, treatment and control of

hypertension among United States Adults 1999-2004. Hypertens 2007;

49: 69-75

(2) Margolis et al. Blood Pressure Control
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
3. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
4. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
5. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
6. Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
9. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
10. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Today,s New ... "Plan for Kidney Drugs Spurs Division," illustrates an ... in kidney patients continuing to be deprived of ... Medicare program limit. ,, As Congress is poised ... preserve the lives of transplant kidney recipients, behind-the-scenes ...
(Date:12/15/2009)... YORK, Dec. 15 ,, Reportlinker.com ... is available in its catalogue: ,, ... Market Forecasts to 2015 ,, ... Pipeline Analysis and Market Forecasts to 2015 ... industry analysis specialist,s new report, "Hepatitis B ...
(Date:12/15/2009)... Dec. 15 Waters Corporation (NYSE: ... Vision Publisher(TM) (v.7.1 SR4), an electronic laboratory notebook ... (SDMS), a secure electronic repository that stores and ... centralized database and is used to boost efficiency ... with the SAFE-BioPharma digital identity and signature standard. ...
Breaking Medicine Technology:AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 2Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 3Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 4Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 5Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 1Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 5Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 7Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 8Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 9Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 10QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 1QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 2QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 3QlikTech Wins Healthcare IT Innovation 26amp 3B 238482 3B Award 61914 4Tis the Season to Eat and Eat More 21 61910 1Tis the Season to Eat and Eat More 21 61910 2
... Combination Clinical Trials ... SOUTH SAN FRANCISCO, Calif., June 16 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... the company,s lead drug candidate, voreloxin (formerly,SNS-595), including updated results ... single agent in relapsed or refractory patients with acute,myeloid leukemia ...
... 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) ... survival,from its Phase 2b clinical trial of CoFactor ... survival results in this,study have been revised upwards ... day improvement in overall survival,compared to the leucovorin/5-FU ...
Other Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 2ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results 3
(Date:12/15/2009)... Our Lady of Lourdes Health Care Services ... has agreed to pay the United States $7.95 million ... Justice Department announced today. The two hospitals are Our ... and Lourdes Medical Center of Burlington County (LMC) in ... a suit brought by a whistleblower, Tony Kite, in ...
(Date:12/15/2009)... associated with lower dementia risk, research finds , , TUESDAY, ... leptin, a hormone that regulates appetite, may guard against ... or 15 years this may be one of many ... Alzheimer,s disease," said senior study author Dr. Sudha Seshadri, ... of Medicine. "Or it may be one of many ...
(Date:12/15/2009)... sobering statistics concerning the parallel rise in diabetes and obesity rates ... of combating this trend afflicting their workforce. , ... ... climbing across America due in large part to the alarming parallel ... has stated that the rate of diabetes could be cut in ...
(Date:12/15/2009)... Dec. 15 Knowledge ... the pharmaceutical and bio-tech research market with ... Over the past 11 years CMR has ... Consulting Network (PCN®), which now includes 70,000 ... both primary care and hard-to-reach specialties. ...
(Date:12/15/2009)... -- Patient advocate Betsy McCaughey, ... Congress that, "it doesn,t matter whether there,s a public ... a public option - give government authority over how ... a new social agenda by shifting billions of dollars ... arriving immigrants, and local politicians." ,, Betsy ...
Breaking Medicine News(10 mins):Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2
... Scientists have identified the role of two proteins that ... classes of antibiotics. , The finding is a step ... resistance at its cellular source. Before researchers can design ... at play in the conflict between bacteria and the ...
... They wear Prada. They do Pilates.,They primp and pluck. ... other big event -- also take advantage of high-tech ... to Dr. Cameron Rokhsar, a Board-Certified Dermatologic,Surgeon who has ... as in his Upper East Side NY practice, explains ...
... offer up personal history, researchers say , , MONDAY, ... stays in your hair, and it may reveal details ... analyzing the makeup of water molecules from human hair, ... the regions where people recently lived. While the approach ...
... TORRANCE Combined hormone therapy appears to increase the ... biopsies, and it may decrease the effectiveness of both ... in the Feb. 25 issue of Archives of Internal ... Chlebowski, M.D., Ph.D., a lead investigator at the Los ...
... ST. LOUIS, Feb. 25 Stereotaxis, Inc. (Nasdaq:,STXS) announced ... the,fourth quarter and full year ended December 31, 2007, ... Company will host a conference call,and webcast on Wednesday, ... the Company,s fourth quarter results and current corporate,developments. The ...
... living, evading antibiotic drugs while killing tens of thousands of ... about drug-resistant bacteria grows, one novel approach under way at ... thwart the bug without a drug by taking a cue ... analytical chemists at UNC have created nano-scale scaffolds made of ...
Other Medicine News:Health News:Scientists identify proteins that help bacteria put up a fight 2Health News:Scientists identify proteins that help bacteria put up a fight 3Health News:Oscar Makeover CHEAT Secrets of the Stars Revealed 2Health News:Hair Tells Tale of Where You've Been 2Health News:Hair Tells Tale of Where You've Been 3Health News:LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies 2Health News:Silica smart bombs deliver knock-out to bacteria 2
... new biological material produced from ... implant, lyoplant can absorb in ... implant material with the recipient's ... minimizes suture channels, resulting in ...
Elmed electrosurgical systems for major surgery....
Adson bipolar forceps, 12 cm, straight....
Straight, blunt and pointed tips....
Medicine Products: